联邦制药成立于1990 年,于2007 年在香港上市,主要从事药品的研发、生产及销售。历经三十余年发展,联邦制药形成了拥有制剂、原料、生物、动保四大业务板块;在研方面,聚焦代谢/自免领域,已完成大额授权。减重:UBT251 已实现授权,司美格鲁肽仿制药已进入临床UBT251 中国Ib 期超重/肥胖适应症临床试验结果显示:给药第12 周,最高剂量组平均体重较基线下降15.1%,安慰剂组较基线平均增加...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.